Analysts Have Drastically Reduced Biogen’s Target Price in March
What Analysts Are Recommending for These Biotech Giants in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 13.56% for Biogen (BIIB) based on its closing price on March